Vanguard Group Inc. Decreases Stock Position in Travere Therapeutics, Inc. $TVTX

Vanguard Group Inc. reduced its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 4.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,309,229 shares of the company’s stock after selling 304,139 shares during the period. Vanguard Group Inc. owned about 0.07% of Travere Therapeutics worth $241,076,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC purchased a new position in Travere Therapeutics in the 4th quarter worth approximately $438,000. Calamos Advisors LLC purchased a new position in Travere Therapeutics in the 4th quarter worth approximately $2,763,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Travere Therapeutics by 20.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,877 shares of the company’s stock worth $1,180,000 after acquiring an additional 5,344 shares during the last quarter. First Horizon Corp raised its holdings in Travere Therapeutics by 112.1% in the 4th quarter. First Horizon Corp now owns 3,236 shares of the company’s stock worth $124,000 after acquiring an additional 1,710 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Travere Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,348 shares of the company’s stock worth $166,000 after acquiring an additional 902 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Travere Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Wells Fargo & Company lifted their target price on shares of Travere Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday. Piper Sandler raised shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price for the company in a research report on Tuesday, April 14th. TD Cowen lifted their target price on shares of Travere Therapeutics from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Guggenheim lifted their target price on shares of Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $47.83.

Travere Therapeutics Trading Down 0.1%

NASDAQ:TVTX opened at $42.60 on Friday. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $48.61. The company has a market cap of $3.96 billion, a PE ratio of -185.21 and a beta of 1.13. The company has a 50 day simple moving average of $32.83 and a two-hundred day simple moving average of $32.94.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same quarter in the previous year, the firm posted ($0.47) EPS. The firm’s revenue was up 55.6% on a year-over-year basis. Research analysts forecast that Travere Therapeutics, Inc. will post -0.24 earnings per share for the current year.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Insider Transactions at Travere Therapeutics

In other news, insider Elizabeth E. Reed sold 2,076 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $91,240.20. Following the completion of the sale, the insider directly owned 105,211 shares in the company, valued at $4,624,023.45. This represents a 1.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider William E. Rote sold 2,763 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $121,433.85. Following the completion of the sale, the insider owned 115,474 shares of the company’s stock, valued at $5,075,082.30. This trade represents a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 400,015 shares of company stock worth $15,895,428 over the last three months. 4.44% of the stock is currently owned by insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.